Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,089 JPY | -0.02% | 0.00% | +0.86% |
05:40pm | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
05:10pm | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company appears to be poorly valued given its net asset value.
- The company is one of the best yield companies with high dividend expectations.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an expected P/E ratio at 46.41 and 27.61 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.86% | 41.26B | B+ | ||
+26.06% | 653B | C+ | ||
+27.00% | 556B | B | ||
-6.59% | 354B | C+ | ||
+20.37% | 331B | B- | ||
+2.62% | 296B | C+ | ||
+13.09% | 233B | B+ | ||
+5.46% | 201B | B- | ||
-9.61% | 193B | A+ | ||
-6.44% | 144B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4502 Stock
- Ratings Takeda Pharmaceutical Company Limited